Breast Cancer Clinical Trial
— PACT001Official title:
A Phase II Trial of Neoadjuvant Arimidex With or Without Faslodex in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Verified date | July 2020 |
Source | Baylor Breast Care Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Over the last 3 decades, a steady shift has occurred in the management of breast cancer.
Because it was traditionally viewed as a local disease, many advocated the use of radical
surgery to achieve maximum survival benefit. This view has been slowly replaced by a broader
biologic view that recognizes the often systemic nature of breast cancer, even when it
appears to be localized to the breast. Results from randomized clinical trials have
demonstrated that less extensive surgery, or lumpectomy plus radiation therapy, are optimal
for local management of early breast cancer. In addition to the less radical approach to
surgical treatment of breast cancer, other randomized clinical trials have established the
value of postoperative systemic therapy in improving overall survival by eradicating
micrometastatic disease, the major cause of mortality from breast cancer. Despite the
well-documented benefits of adjuvant systemic therapy, it is not effective in preventing
death from breast cancer in all patients who are candidates for such treatment. The worth of
such therapy can only be judged in retrospect upon disease relapse, a time when breast cancer
is nearly always incurable. Currently, there are few reliable methods to predict the success
or failure of a particular postoperative treatment modality, and better ways to predict and
optimize outcome are needed.
Combination endocrine therapy: Using endocrine agents with different mechanisms of action
together has the potential advantage of more effectively blocking ER signaling, thus
improving the efficacy of such agents against breast cancer. In the past, attempts to combine
endocrine agents for ER-positive breast cancer have had mixed results, depending on the
setting and the patient population studied.
Endocrine agents without any agonist effect could potentially be used in combination with
aromatase inhibitors, under the rationale that the combination would maximally blockade
estrogen receptor signaling, thus potentially improving the antitumor effect. Fulvestrant
(FASLODEX) is a pure estrogen antagonist with no known agonist effect; thus, it has the
potential to provide additional benefit when combined with an aromatase inhibitor. This
concept provides the rationale for using the combination of anastrazole and fulvestrant in
this study.
Status | Completed |
Enrollment | 72 |
Est. completion date | December 5, 2018 |
Est. primary completion date | October 2016 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - All subjects must be female. - Postmenopausal status, defined as any one of the following criteria: - Documented history of bilateral oophorectomy. - Age 60 years or more. - Age 45 to 59 and satisfying one or more of the following criteria: - Amenorrhea for at least 12 months and intact uterus. - Amenorrhea for less than 12 months and a follicle stimulating hormone (FSH) and estradiol concentration within postmenopausal range including: patients who have had a hysterectomy and patients who have received hormone replacement. - Patients must have histologically confirmed invasive breast cancer with a primary tumor of 3 cm or more in greatest dimension as measured by clinical examination. - Estrogen receptor and/or progesterone receptor positive disease. - Patients must not have received any prior treatment for current or newly diagnosed breast cancer. - Patients must have not received previous treatment with any of the study medications or similar drugs. - No use of selective estrogen receptor modulators (SERM) such as raloxifene or similar agents in the past 2 years. - WHO performance status of 0, 1, or 2. - Adequate organ function defined as follows: - Adequate renal function, defined by a serum creatinine within 3 times the upper limits of normal. - Adequate liver function, defined by total bilirubin, AST, ALT, and alkaline phosphatase within 3 times the upper limits of normal. - Adequate bone marrow function, defined as a WBC greater than 3.0 ml, PLT greater than 75,000/ul, Hb greater than 9 gm/l. - Willing to undergo breast core biopsies as required by the study protocol. - Ability to understand and sign a written informed consent for participation in the trial. - Life expectancy of at least 1 year. Exclusion Criteria: - Premenopausal status. - Other coexisting malignancies with the exception of basal cell carcinoma or cervical cancer in situ. - Patients with brain metastasis. - WHO performance status of 3 or 4. - Is judged by the investigator, uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the clinical trial. - Concurrent treatment with estrogens or progestins. Patients must stop these drugs at least two weeks prior to study entry. - Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment. - Platelet count less than 75,000. - In the opinion of the investigator, bleeding diathesis or anticoagulation therapy that would preclude intramuscular injections. - History of hypersensitivity to castor oil. - Any evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded) - Patients with recurrent breast cancer. - Patients with contralateral second primary breast cancers are eligible. |
Country | Name | City | State |
---|---|---|---|
United States | Baylor College of Medicine | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
Mothaffar Rimawi | AstraZeneca |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Ki-67 Levels From Baseline (Pre) to Day 28 (Post) Biopsy Samples | The primary endpoint is change in Ki-67 levels from baseline (pre) to day 28 (post) biopsy samples. Ki-67 levels were log-transformed to achieve approximately normally distributed data. The differences in these log-transformed values between post vs. pre biopsy samples were calculated. This difference represents the log of the ratio of post vs. pre Ki-67 levels in the original scale. | baseline (pre) to day 28 (post) | |
Secondary | Clinical Response | Measurable lesions were examined at baseline to treatment completion.Clinical Response was defined by Solid Tumor Response Criteria (RECIST). | 1 Year | |
Secondary | Pathologic Complete Response | Pathologic response was defined as no residual invasive tumor on histopathological analysis in the breast primary. Patients were assessed according to the Chevallier classification of pathologic response. | 1 Year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |